Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Jang v. Boston Scientific Corporation
Case Number:
16-1275
Court:
Nature of Suit:
830 Patent Infringement (Fed. Question)
Companies
Sectors & Industries:
-
December 21, 2017
Full Fed Circ. Won't Review Boston Sci Win In $200M IP Suit
The Federal Circuit on Thursday summarily denied en banc review of a cardiologist's $200 million contract lawsuit seeking royalties from Boston Scientific on his stent patents, rejecting the doctor's claim that the company unfairly used a rare ensnarement defense.
-
November 20, 2017
Fed. Circ. Urged To Not Review Defense In $200M Patent Suit
Boston Scientific urged the Federal Circuit on Friday not to rethink a holding that the company is shielded from liability by the rarely invoked ensnarement defense in a cardiologist's contract suit seeking more than $200 million in royalties on his stent patents, saying its use of the defense didn't come as a surprise.
-
October 31, 2017
Full Fed Circ. Asked To Review Ensnarement In $200M IP Suit
The cardiologist who lost a contract suit seeking $200 million in royalties from Boston Scientific on his stent patents told the Federal Circuit in an en banc rehearing motion Monday that the company's use of the rare ensnarement defense "was the height of unfair surprise" and should have been disallowed.
-
October 24, 2017
Ensnarement 101: Anatomy Of An Uncommon Patent Defense
A recent Federal Circuit decision clearing Boston Scientific Corp. in a $200 million patent case drew attention to the rarely invoked ensnarement defense to infringement. Here's a primer on how the defense works and why attorneys say accused infringers should consider using it more often.
-
September 29, 2017
Fed. Circ. Clears Boston Scientific In $200M Stent IP Case
The Federal Circuit on Friday upheld a decision clearing Boston Scientific Corp. in a cardiologist's contract suit seeking more than $200 million in royalties on his stent patents, concluding that the company is shielded from liability by the rarely invoked ensnarement defense.
-
August 11, 2017
Fed. Circ. Pushed To Revive $200M Boston Scientific IP Suit
A California cardiologist claiming that Boston Scientific Corp. owes him more than $200 million in royalty payments for using his patented stent technology argued to a Federal Circuit panel Friday that a trial court improperly threw out a favorable infringement verdict under the rarely used "ensnarement" defense.